The FDA has approved a new blood test for colorectal cancer named Shield, developed by Guardant Health. This test, which requires only a blood sample, detects early-stage cancers and some polyps by identifying DNA fragments shed by cancer cells. Shield is designed for individuals aged 45 and older who are at average risk for colon cancer.
Keeran Sampat, MD, Virginia Cancer Specialists, Arlington Office – emphasizes that the Shield blood test is a promising development that could enhance screening rates for colon cancer, a disease that is highly curable when detected early. He notes, “The recent FDA approval for the ‘Shield’ blood DNA test is a promising development that could help improve screening rates for colon cancer. Having several screening tools including traditional colonoscopies, stool DNA testing, and now blood testing will hopefully help save lives. The choice of which screening option is appropriate should be discussed with a physician. We should remember that both stool and blood testing have some limitations in detecting precancerous polyps when making the decision about which test to pursue.”
While the Shield test offers a simpler alternative to colonoscopies and fecal tests, it has notable limitations. Specifically, it struggles to detect precancerous polyps, which are important for cancer prevention. The test has a 10% false positive rate and identifies only 13% of large polyps, compared to 95% with colonoscopies.
Despite these limitations, the convenience of a blood test may encourage more people to undergo screening, potentially improving overall detection rates. Medicare will cover the test for eligible individuals, but out-of-pocket costs for those with commercial insurance or Medicare Advantage will vary. To ensure you are taking the best steps for your health, we encourage you to contact your primary care provider to schedule a screening and discuss whether the Shield test or another screening option is right for you. Early detection can make a crucial difference, so take action today to protect your health!
Source ASCO: Guardant Health’s Shield Blood Test Approved by the FDA as a Primary Screening Option for Colorectal Cancer
